RESUMO
To study the efficacy and safety of a parenteral formulation of 'Manyana' (a combination of diclofenac + pitofenone + fenpiverinium) in ureteric, biliary and intestinal colic, an open labelled study was conducted at two centres. A total of 206 patients were enrolled and evaluated for decrease in pain with time on a visual analogue scale. A statistically significant difference was observed in pain within 30 minutes of drug administration and the pain relief lasted for as long as 24 hours post dosing. The study shows definite synergism between the antispasmodics pitofenone and fenpiverinium with the NSAID-diclofenac, reducing the prostaglandin levels and also the spasm related to colic.
Assuntos
Adolescente , Adulto , Anti-Inflamatórios não Esteroides/uso terapêutico , Benzofenonas/uso terapêutico , Doenças Biliares/tratamento farmacológico , Cólica/tratamento farmacológico , Diclofenaco/uso terapêutico , Combinação de Medicamentos , Feminino , Humanos , Injeções Intramusculares , Enteropatias/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Parassimpatolíticos/uso terapêutico , Piperidinas/uso terapêutico , Doenças Ureterais/tratamento farmacológicoRESUMO
In this double blind, prospective study, the relative efficacy of Diclofenac + Pitofenone + Fenpiverinium (Manyana) and Analgin + Pitofenone + Fenpiverinium (Baralgan) in 200 patients of biliary, ureteric and intestinal colic was evaluated. Patients were given these coded drugs thrice daily for five days starting from day 0 to day 5. The results of the present clinical evaluation demonstrated that Manyana appeared to be superior to Baralgan in biliary and ureteric colic while it was therapeutically equivalent to Baralgan in reducing the pain intensity in intestinal colic. Both the medications were tolerated well and there were no side-effects reported.